Same Drug Class

Pembrolizumab vs Tofacitinib

Pembrolizumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Tofacitinib.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days; Tofacitinib — 3.2 hours.

Chemical Properties

Molecular Formula: Tofacitinib — C16H20N6O.

Molecular Weight: Tofacitinib — 312.3700 g/mol.

Type: Pembrolizumab — Antibody; Tofacitinib — Small molecule.